ERBB2 and breast carcinoma: As previously reported [22] the HER2-positive breast cancer cell lines HCC1954, BT474 and SKBR3 are sensitive to copanlisib and lapatinib at nM concentrations (Table 1), whilst only BT474 and SKBR3 cells have sensitivity in vitro to trastuzumab.